|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
NZ542873A
(en)
|
2003-03-05 |
2008-07-31 |
Halozyme Inc |
Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
US20120230991A1
(en)
*
|
2008-07-29 |
2012-09-13 |
Douglas Kim Graham |
Methods and compounds for enhancing anti-cancer therapy
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
EP3508215A3
(en)
|
2012-12-03 |
2019-10-02 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
SMT202100065T1
(it)
|
2013-05-02 |
2021-03-15 |
Anaptysbio Inc |
Anticorpi diretti contro la proteina della morte programmata (pd-1)
|
|
WO2014194302A2
(en)
|
2013-05-31 |
2014-12-04 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
SG10201804945WA
(en)
|
2013-12-12 |
2018-07-30 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
CA2972048C
(en)
*
|
2014-12-22 |
2023-03-07 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
|
DK3237446T3
(en)
|
2014-12-22 |
2021-07-26 |
Pd 1 Acquisition Group Llc |
Anti-PD-1-antistoffer
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
|
EP4458417A3
(en)
|
2015-08-11 |
2025-02-19 |
Wuxi Biologics Ireland Limited |
Novel anti-pd-1 antibodies
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
AU2016317915B2
(en)
|
2015-09-01 |
2021-02-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
|
IL260021B
(en)
|
2015-12-14 |
2022-09-01 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
|
|
US11814679B2
(en)
|
2016-01-11 |
2023-11-14 |
Eli Lilly And Company |
Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of same
|
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
JP2020526584A
(ja)
|
2017-06-28 |
2020-08-31 |
ザ ロックフェラー ユニバーシティー |
抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用
|